Research map: First-line treatment patterns and real-world survival outcomes in PD-L1-negative locally recurrent inoperable or metastatic triple-negative breast cancer in the United States

Back to the article

Papers in this map

  1. Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence · Rebecca Alexandra Dent · 2007 · 5230 citations · Cited by this paper
  2. Retrospective study on regional nodal irradiation after omission of axillary lymph node dissection in sentinel lymph node-positive breast cancer: a propensity score matching analysis · 2026 · Related
  3. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer · Javier Cortés · 2022 · 1196 citations · Cited by this paper
  4. Factors influencing discussion duration in breast cancer multidisciplinary team meetings: insights for streamlining care · 2026 · Related
  5. Triple negative breast cancer: Pitfalls and progress · Paola Zagami · 2022 · 848 citations · Cited by this paper
  6. Antacid co-treatment and pregnane X receptor genetic polymorphisms are survival determinants in patients treated with palbociclib · 2026 · Related
  7. Survival Outcomes for Patients with Metastatic Triple-Negative Breast Cancer: Implications for Clinical Practice and Trial Design · Farrah Kassam · 2009 · 484 citations · Cited by this paper
  8. Curative-intent stereotactic ablative body radiation, surgery, and systemic therapy in non-osseous oligometastatic breast cancer · 2026 · Related
  9. Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer · Javier Cortés · 2025 · 86 citations · Cited by this paper
  10. Early first-line systemic anticancer therapeutic attrition after metastatic recurrence in triple-negative breast cancer following neoadjuvant chemo-immunotherapy: a multicenter real-world study · 2026 · Related
  11. End-Stage Renal Disease-Associated Managed Care Costs Among Patients With and Without Diabetes · Amie T. Joyce · 2004 · 77 citations · Cited by this paper
  12. Abemaciclib rechallenge after progression on abemaciclib plus endocrine therapy in patients with hormone receptor-positive HER2-negative metastatic breast cancer: results from the phase II again study (WJOG14220B) · 2026 · Related
  13. Overall Survival and Prognostic Factors in Metastatic Triple-Negative Breast Cancer: A National Cancer Database Analysis · Meghana Kesireddy · 2024 · 60 citations · Cited by this paper
  14. Age-stratified difference in patient-reported health-related quality of life following breast cancer surgery · 2026 · Related
  15. Real-World Effectiveness Outcomes in Patients Diagnosed with Metastatic Triple-Negative Breast Cancer · Karen E Skinner · 2020 · 55 citations · Cited by this paper
  16. Rediscovering the Ciucci pathway: in-vivo evidence of a palmar lymphatic channel · 2026 · Related
  17. Unmet need for previously untreated metastatic triple-negative breast cancer: a real-world study of patients diagnosed from 2011 to 2022 in the United States · Kevin Punie · 2025 · 33 citations · Cited by this paper
  18. New Treatment Approaches for Triple-Negative Breast Cancer · Fauzia Riaz · 2025 · 29 citations · Cited by this paper
  19. Impact of histotypes on preferential organ‐specific metastasis in triple‐negative breast cancer · Yaming Li · 2019 · 27 citations · Cited by this paper
  20. Prognostic Significance and Molecular Classification of Triple Negative Breast Cancer: A Systematic Review · Ashok Kumar Dogra · 2025 · 26 citations · Cited by this paper
  21. Impact of Nonconcordance With NCCN Guidelines on Resource Utilization, Cost, and Mortality in De Novo Metastatic Breast Cancer · Gabrielle Betty Rocque · 2018 · 25 citations · Cited by this paper
  22. Genomic characterization reveals distinct mutational landscapes and therapeutic implications between different molecular subtypes of triple-negative breast cancer · Ruo Qi Li · 2024 · 21 citations · Cited by this paper
  23. Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database · Coralie Courtinard · 2023 · 19 citations · Cited by this paper
  24. Treatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021 · Rachel Jaber Chehayeb · 2022 · 18 citations · Cited by this paper
  25. Real-World Outcomes in Metastatic HR+/HER2-, HER2+ and Triple Negative Breast Cancer after Start of First-Line Therapy · Richard W DeClue · 2023 · 12 citations · Cited by this paper
  26. Real-World Survival and Treatment Regimens Across First- to Third-Line Treatment for Advanced Triple-Negative Breast Cancer · Alan Celik · 2023 · 12 citations · Cited by this paper
  27. Overall survival of patients with de Novo HER2-positive metastatic breast cancer in the Netherlands from 2008 to 2017: A population-based cohort study of systemically treated patients · Nan Ding · 2025 · 9 citations · Cited by this paper
  28. Real-World Treatment Patterns and Outcomes for Patients With Metastatic Triple-Negative Breast Cancer in the United States: An Observational Study · Simon M. Collin · 2026 · 4 citations · Cited by this paper
  29. Treatment Patterns, Clinical Events, and Costs of Care for Patients With Triple Negative Metastatic Breast Cancer: A Retrospective US Claims Database Study · Manali A. Bhave · 2025 · 2 citations · Cited by this paper
  30. Untitled · Cited by this paper

Source: OpenAlex (CC0)